Ultrasound guidance for transfemoral access in coronary procedures: an individual participant-level data metaanalysis from the femoral ultrasound trialist collaboration.
Journal
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
pmc-release:
01
01
2025
medline:
3
1
2024
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
ppublish
Résumé
Randomised controlled trials of ultrasound (US)-guided transfemoral access (TFA) for coronary procedures have shown mixed results. We aimed to compare US-guided versus non-US-guided TFA from randomised data in an individual participant-level data (IPD) meta-analysis. We completed a systematic review and an IPD meta-analysis of all randomised controlled trials comparing US-guided versus non-US-guided TFA for coronary procedures. We performed a one-stage mixed-model meta-analysis using the intention-to-treat population from included trials. The primary outcome was a composite of major vascular complications or major bleeding within 30 days. A total of 2,441 participants (1,208 US-guided, 1,233 non-US-guided) from 4 randomised clinical trials were included. The mean age was 65.5 years, 27.0% were female, and 34.5% underwent a percutaneous coronary intervention. The incidence of major vascular complications or major bleeding (34/1,208 [2.8%] vs 55/1,233 [4.5%]; odds ratio [OR] 0.61, 95% confidence interval [CI]: 0.39-0.94; p=0.026) was lower in the US-guided TFA group. In the prespecified subgroup of participants who received a vascular closure device, those randomised to US-guided TFA experienced a reduction in the primary outcome (2.1% vs 5.6%; OR 0.36, 95% CI: 0.19-0.69), while no benefit for US guidance was observed in the subgroup without vascular closure devices (4.1% vs 3.3%; OR 1.21, 95% CI: 0.65-2.26; interaction p=0.009). In participants undergoing coronary procedures by TFA, US guidance decreased the composite outcome of major vascular complications or bleeding and may be especially helpful when using vascular closure devices.
Sections du résumé
BACKGROUND
BACKGROUND
Randomised controlled trials of ultrasound (US)-guided transfemoral access (TFA) for coronary procedures have shown mixed results.
AIMS
OBJECTIVE
We aimed to compare US-guided versus non-US-guided TFA from randomised data in an individual participant-level data (IPD) meta-analysis.
METHODS
METHODS
We completed a systematic review and an IPD meta-analysis of all randomised controlled trials comparing US-guided versus non-US-guided TFA for coronary procedures. We performed a one-stage mixed-model meta-analysis using the intention-to-treat population from included trials. The primary outcome was a composite of major vascular complications or major bleeding within 30 days.
RESULTS
RESULTS
A total of 2,441 participants (1,208 US-guided, 1,233 non-US-guided) from 4 randomised clinical trials were included. The mean age was 65.5 years, 27.0% were female, and 34.5% underwent a percutaneous coronary intervention. The incidence of major vascular complications or major bleeding (34/1,208 [2.8%] vs 55/1,233 [4.5%]; odds ratio [OR] 0.61, 95% confidence interval [CI]: 0.39-0.94; p=0.026) was lower in the US-guided TFA group. In the prespecified subgroup of participants who received a vascular closure device, those randomised to US-guided TFA experienced a reduction in the primary outcome (2.1% vs 5.6%; OR 0.36, 95% CI: 0.19-0.69), while no benefit for US guidance was observed in the subgroup without vascular closure devices (4.1% vs 3.3%; OR 1.21, 95% CI: 0.65-2.26; interaction p=0.009).
CONCLUSIONS
CONCLUSIONS
In participants undergoing coronary procedures by TFA, US guidance decreased the composite outcome of major vascular complications or bleeding and may be especially helpful when using vascular closure devices.
Identifiants
pubmed: 37800723
pii: EIJ-D-22-00809
doi: 10.4244/EIJ-D-22-00809
pmc: PMC10758987
pii:
doi:
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
66-74Références
J Clin Med. 2020 Mar 03;9(3):
pubmed: 32138283
JACC Cardiovasc Interv. 2010 Jul;3(7):751-8
pubmed: 20650437
J Invasive Cardiol. 2016 Aug;28(8):311-4
pubmed: 27466273
J Invasive Cardiol. 2015 Jul;27(7):318-23
pubmed: 26136279
JACC Cardiovasc Interv. 2015 Dec 21;8(14):1854-64
pubmed: 26604063
J Interv Cardiol. 2018 Aug;31(4):496-503
pubmed: 29372578
Circulation. 2022 Nov;146(18):1329-1343
pubmed: 36036610
Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1187-92
pubmed: 23592533
JACC Cardiovasc Interv. 2008 Apr;1(2):202-9
pubmed: 19463301
Int J Cardiovasc Imaging. 2004 Oct;20(5):363-8
pubmed: 15765858
Stat Med. 2017 Feb 28;36(5):855-875
pubmed: 27747915
JAMA. 2015 Apr 28;313(16):1657-65
pubmed: 25919529
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
JACC Cardiovasc Interv. 2011 Jun;4(6):654-64
pubmed: 21700252
Int J Evid Based Healthc. 2015 Sep;13(3):196-207
pubmed: 26355603
J Vasc Surg. 2020 Jul;72(1):259-267
pubmed: 31980242
EuroIntervention. 2019 Aug 09;15(6):e522-e530
pubmed: 31113763
Circ Cardiovasc Interv. 2021 Oct;14(10):e010742
pubmed: 34538068
Can J Cardiol. 2023 Oct;39(10):1392-1396
pubmed: 37211041
JAMA Cardiol. 2022 Nov 1;7(11):1110-1118
pubmed: 36116089
EuroIntervention. 2023 May 15;19(1):73-79
pubmed: 36876864
JACC Cardiovasc Interv. 2017 Nov 27;10(22):2269-2279
pubmed: 29169496
Acta Cardiol Sin. 2018 Sep;34(5):394-398
pubmed: 30271089
Cardiovasc Intervent Radiol. 2015 Jun;38(3):579-82
pubmed: 25338833
J Invasive Cardiol. 2019 Jul;31(7):E192-E198
pubmed: 31257213
Interact Cardiovasc Thorac Surg. 2018 Sep 1;27(3):317-321
pubmed: 29868857
Cardiovasc Revasc Med. 2022 May;38:61-67
pubmed: 34556431
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242